Otsuka and Lundbeck’s CNS drug Rexulti has for the second time this year claimed the top spot as the leading TV drug ad spender. That’s according to the latest data out by real-time ad trackers ...
As we hit the middle of the year, AbbVie is comfortably back in the top TV drug ad spenders’ driving seat taking the top two spots in July with its immunology blockbuster duo Skyrizi and Rinvoq, ...
Please provide your email address to receive an email when new articles are posted on . The FDA has accepted a supplemental new drug application from Otsuka and Lundbeck for Rexulti in combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback